Marc Frahm
Stock Analyst at TD Cowen
(4.90)
# 258
Out of 4,639 analysts
409
Total ratings
55.7%
Success rate
25.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Marc Frahm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRDF Cardiff Oncology | Maintained: Hold | n/a | $1.05 | - | 17 | Aug 11, 2026 | |
| RVMD Revolution Medicines | Reiterated: Buy | $205 | $205.55 | -0.19% | 27 | Aug 10, 2026 | |
| DMRA Damora Therapeutics | Maintained: Buy | n/a | $30.36 | - | 3 | Aug 10, 2026 | |
| SRRK Scholar Rock Holding | Maintained: Buy | n/a | $52.07 | - | 25 | Aug 9, 2026 | |
| PBYI Puma Biotechnology | Maintained: Hold | $5 → $6 | $8.77 | -31.58% | 12 | Aug 7, 2026 | |
| BDTX Black Diamond Therapeutics | Maintained: Buy | n/a | $2.09 | - | 16 | Aug 5, 2026 | |
| AGIO Agios Pharmaceuticals | Maintained: Buy | n/a | $32.69 | - | 26 | Aug 3, 2026 | |
| INCY Incyte | Maintained: Buy | $124 → $138 | $121.07 | +13.98% | 72 | Jul 28, 2026 | |
| CGEM Cullinan Therapeutics | Maintained: Buy | n/a | $19.63 | - | 26 | Jun 10, 2026 | |
| ACRV Acrivon Therapeutics | Maintained: Buy | n/a | $1.73 | - | 12 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $3.79 | - | 14 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $75.50 | - | 2 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $15 | $16.92 | -11.35% | 19 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $16.52 | - | 18 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $7.18 | - | 13 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $15.76 | - | 16 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $109.62 | - | 22 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $9.18 | - | 10 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $0.0264 | n/a | 19 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $4.28 | n/a | 8 | Jan 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $108.49 | n/a | 10 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $150,000.00 | n/a | 6 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $3.03 | n/a | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $2.12 | n/a | 3 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $38.70 | n/a | 5 | Feb 26, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1,215.02 | n/a | 1 | Jan 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $359.27 | n/a | 6 | Dec 4, 2018 |
Cardiff Oncology
Aug 11, 2026
Maintained: Hold
Price Target: n/a
Current: $1.05
Upside: -
Revolution Medicines
Aug 10, 2026
Reiterated: Buy
Price Target: $205
Current: $205.55
Upside: -0.19%
Damora Therapeutics
Aug 10, 2026
Maintained: Buy
Price Target: n/a
Current: $30.36
Upside: -
Scholar Rock Holding
Aug 9, 2026
Maintained: Buy
Price Target: n/a
Current: $52.07
Upside: -
Puma Biotechnology
Aug 7, 2026
Maintained: Hold
Price Target: $5 → $6
Current: $8.77
Upside: -31.58%
Black Diamond Therapeutics
Aug 5, 2026
Maintained: Buy
Price Target: n/a
Current: $2.09
Upside: -
Agios Pharmaceuticals
Aug 3, 2026
Maintained: Buy
Price Target: n/a
Current: $32.69
Upside: -
Incyte
Jul 28, 2026
Maintained: Buy
Price Target: $124 → $138
Current: $121.07
Upside: +13.98%
Cullinan Therapeutics
Jun 10, 2026
Maintained: Buy
Price Target: n/a
Current: $19.63
Upside: -
Acrivon Therapeutics
May 14, 2026
Maintained: Buy
Price Target: n/a
Current: $1.73
Upside: -
May 11, 2026
Maintained: Buy
Price Target: n/a
Current: $3.79
Upside: -
May 8, 2026
Reiterated: Buy
Price Target: n/a
Current: $75.50
Upside: -
May 8, 2026
Rated: Hold
Price Target: $15
Current: $16.92
Upside: -11.35%
May 8, 2026
Maintained: Buy
Price Target: n/a
Current: $16.52
Upside: -
May 7, 2026
Maintained: Buy
Price Target: n/a
Current: $7.18
Upside: -
May 7, 2026
Reiterated: Buy
Price Target: n/a
Current: $15.76
Upside: -
May 5, 2026
Maintained: Buy
Price Target: n/a
Current: $109.62
Upside: -
Nov 13, 2025
Maintained: Buy
Price Target: n/a
Current: $9.18
Upside: -
Nov 14, 2024
Maintained: Buy
Price Target: n/a
Current: $0.0264
Upside: n/a
Jan 12, 2024
Rated: Hold
Price Target: n/a
Current: $4.28
Upside: n/a
Jan 26, 2023
Downgraded: Hold
Price Target: n/a
Current: $108.49
Upside: n/a
Mar 22, 2021
Downgraded: Hold
Price Target: n/a
Current: $150,000.00
Upside: n/a
Mar 2, 2021
Initiated Coverage: Buy
Price Target: n/a
Current: $3.03
Upside: n/a
Aug 5, 2020
Maintained: Buy
Price Target: n/a
Current: $2.12
Upside: n/a
Feb 26, 2019
Initiated Coverage: Hold
Price Target: n/a
Current: $38.70
Upside: n/a
Jan 7, 2019
Downgraded: Hold
Price Target: n/a
Current: $1,215.02
Upside: n/a
Dec 4, 2018
Maintained: Buy
Price Target: n/a
Current: $359.27
Upside: n/a